Bavarian Nordic could be first on the RSV market in China

A new partnership deal with Nuance Pharma turns Bavarian Nordic’s sights to China. CFO Henrik Juuel opens up about the chance for Bavarian Nordic to be first on the market – a very lucrative position for the firm.
Henrik Juuel, CFO at Bavarian Nordic | Photo: Bavarian Nordic PR
Henrik Juuel, CFO at Bavarian Nordic | Photo: Bavarian Nordic PR
by CHRISTIAN BUNDGAARD, translated by daniel pedersen

The race to the RSV market is fully underway, and on Monday, Bavarian Nordic began sprinting – at least in the direction of the Chinese market.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
  • Must be at least 8 characters, including three of: Uppercase, lowercase, numbers, symbols
    Must contain at least 2 characters
    Must contain at least 2 characters

    Get full access for you and your coworkers

    Start a free company trial today

    Share article

    Sign up for our newsletter

    Stay ahead of development by receiving our newsletter on the latest sector knowledge.

    Newsletter terms

    Front page now

    Further reading